Elliot Offman

机构：Centre for Drug Research and Development, Certara (United States) · ORCID：0000-0002-0012-6506

发表论文 42 篇 · 总被引 745 次 · h-index 17

代表论文

• A Novel NF‐κB Inhibitor, Edasalonexent (CAT‐1004), in Development as a Disease‐Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects (2017 · The Journal of Clinical Pharmacology · 被引 51)
• Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers (2017 · Journal of Cardiovascular Pharmacology and Therapeutics · 被引 33)
• Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelines (2016 · Expert Review of Clinical Pharmacology · 被引 33)
• The Novel GlycoPEGylated FGF21 Analog Pegozafermin Activates Human FGF Receptors and Improves Metabolic and Liver Outcomes in Diabetic Monkeys and Healthy Human Volunteers (2023 · Journal of Pharmacology and Experimental Therapeutics · 被引 32)
• Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer (2020 · Clinical Pharmacokinetics · 被引 23)
• First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer (2025 · Journal for ImmunoTherapy of Cancer · 被引 21)